GoHealth Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

GoHealth heeft een totaal eigen vermogen van $397.3M en een totale schuld van $481.3M, wat de schuld-eigenvermogensverhouding op 121.2% brengt. De totale activa en totale passiva bedragen respectievelijk $1.3B en $943.9M.

Belangrijke informatie

121.2%

Verhouding schuld/eigen vermogen

US$481.33m

Schuld

Rente dekkingsratio	n/a
Contant	US$35.53m
Aandelen	US$397.28m
Totaal verplichtingen	US$943.87m
Totaal activa	US$1.34b

Recente financiële gezondheidsupdates

Recent updates

GoHealth: Turning The Corner On Operating Cash Flow

May 28

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $334.0M ) GOCO } overtreffen de korte termijn passiva ( $282.0M ).

Langlopende schulden: De kortetermijnactiva van GOCO ( $334.0M ) dekken de langetermijnschulden ( $661.9M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 112.2% ) GOCO wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van GOCO is de afgelopen 5 jaar gestegen van 36.7% naar 121.2%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende GOCO voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: GOCO is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 20.1 % per jaar groeit.

GoHealth Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

GoHealth, Inc. Receives Extension Notice from Nasdaq

GoHealth, Inc. announced delayed 10-Q filing

GoHealth, Inc. announced delayed annual 10-K filing

Recent updates

Consensus EPS estimates upgraded to US$1.31 loss

New major risk - Revenue and earnings growth

GoHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

New minor risk - Shareholder dilution

GoHealth, Inc. Appoints Brendan Shanahan as Chief Financial Officer, Effective October 14, 2024

GoHealth, Inc. (NasdaqCM:GOCO) completed the acquisition of e-TeleQuote Insurance, Inc.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

GoHealth, Inc. (NasdaqCM:GOCO) entered into a purchase agreement to acquire e-TeleQuote Insurance, Inc.

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

GoHealth, Inc. Provides Earnings Guidance for the Full Year 2024

New minor risk - Share price stability

GoHealth, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Shareholder dilution

Less than half of directors are independent

GoHealth, Inc. Announces Changes to Board of Directors

New minor risk - Shareholder dilution

New minor risk - Share price stability

New minor risk - Market cap size

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth: Turning The Corner On Operating Cash Flow

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25